• Bausch + Lomb outlined new clinical study results slated for presentation at the ESCRS congress in London on Sept. 11-15.
• Data focus on premium intraocular lenses, dry-eye drops, excimer laser glaucoma therapy, targeting outcomes such as vision quality, satisfaction, safety, effectiveness.
• Real-world and multicenter studies suggest the company’s newer lenses delivered favorable visual and refractive performance with high patient-reported satisfaction.
• Glaucoma procedure studies indicate sustained pressure-lowering benefit with an acceptable safety profile when used alone or alongside cataract surgery.
• Management framed the program as a commercial push in Europe, supported by surgeon education and product demonstrations across its surgical portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.